US Executive Officer Management Changes SEC — April 22, 2026

22-04-2026

At the April 21, 2026 Annual Meeting, Equity Bancshares, Inc. stockholders approved the Second Amendment to the 2022 Omnibus Equity Incentive Plan, increasing authorized Class A common shares by 1,000,000, and ratified Crowe LLP as auditors for 2026 with overwhelming support (18,053,940 For). The Board elected D. Scott Rogerson as a new Class I director following Randee R. Koger's retirement and elected five Class III directors, though some faced significant opposition (e.g., Leon H. Borck: 10,731,420 For vs. 4,737,720 Against; Gregory L. Gaeddert: 10,325,725 For vs. 5,143,415 Against). An advisory vote on 2025 named executive officer compensation passed but with notable dissent (10,134,760 For vs. 5,339,154 Against).

• ·Annual Meeting director election votes: C. Kendric Fergeson - For: 15,433,057; Against: 36,083; Abstain: 26,327
• ·Annual Meeting director election votes: Benjamin M. Hutton - For: 12,961,617; Against: 2,507,529; Abstain: 26,321
• ·Annual Meeting director election votes: Lisa A. Schlehuber - For: 15,444,046; Against: 24,957; Abstain: 26,464
• ·Say-on-pay advisory vote: For: 10,134,760; Against: 5,339,154; Abstain: 21,553
• ·Plan amendment vote: For: 13,875,282; Against: 1,609,920; Abstain: 10,265
• ·Auditor ratification: For: 18,053,940; Against: 79,970; Abstain: 242
• ·Proxy Statement filed March 12, 2026

22-04-2026

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) appointed Charles Duncan, Ph.D., to its Board of Directors effective April 22, 2026, increasing the board to seven members, six of whom are independent. Dr. Duncan, founder of Sulci Advisors, LLC since September 2025 and former Managing Director at Cantor Fitzgerald & Co. and Piper Jaffray & Co., brings nearly three decades of biotechnology equity research experience focused on neurology and psychiatry. He expressed enthusiasm for Vanda's recent approvals of NEREUS™, BYSANTI™, Fanapt® label expansion, and upcoming pipeline data over the next 12 months, signaling a new growth era.

• ·Dr. Duncan served as Managing Director and Senior Biotechnology Analyst at Cantor Fitzgerald from July 2018 to June 2025, covering over 70 companies.
• ·At Piper Jaffray from December 2012 to June 2018, he covered over 40 companies and was recognized by Thomson Reuters StarMine.
• ·Dr. Duncan holds a Ph.D. in Pharmaceutical Sciences (Neuropharmacology) from University of Colorado-Boulder and B.S. in Zoology from University of Wisconsin-Madison.

22-04-2026

On April 17, 2026, Stephen K. Klasko, MD notified DocGo Inc. of his decision to step down from the Board and committees effective at the conclusion of the 2026 Annual Meeting on June 16, 2026, due to a new healthcare leadership role, with no disagreements on company matters. The Board appointed Michael Burdiek as independent Chair and Jim Travers to the Audit and Compliance Committee and Nominating and Corporate Governance Committee, effective around the same time. On April 21, 2026, the Board formed a special committee chaired by Mr. Burdiek with Vina Leite and Ira Smedra to identify corporate efficiencies and cost reductions to accelerate profitability.

• ·Dr. Klasko joined the Board in October 2024.
• ·Special committee appointments effective immediately on April 21, 2026.

22-04-2026

Didier Papadapoulos, President of Aircraft OEM at Joby Aviation, Inc., notified the company of his resignation effective July 3, 2026, to spend time with family and pursue personal interests after five years leading aircraft development efforts. The departure is not due to any disagreement with the company, which expressed gratitude for his contributions and expects him to provide ongoing advisory services.

• ·Resignation notification date: April 20, 2026
• ·Filing signed on April 21, 2026
• ·SEC filing date: April 22, 2026

22-04-2026

David P. Millis, President of Millis Transfer and a director of Heartland Express, Inc., informed the company of his retirement from the presidency effective April 24, 2026, while continuing to serve as a director. In connection with his retirement, Mr. Millis will receive compensation and insurance benefits totaling $66,766 and 4,866 shares of common stock. Post-retirement, he will be eligible for standard non-employee director compensation as outlined in the company's 2026 proxy statement filed on April 2, 2026.

• ·Informed the company of retirement decision on April 16, 2026
• ·8-K filed on April 22, 2026, signed April 21, 2026
• ·Director compensation details in proxy statement filed April 2, 2026

22-04-2026

Best Buy Co., Inc. (NYSE: BBY) announced Jason Bonfig, current Chief Customer, Product and Fulfillment Officer, will succeed Corie Barry as CEO effective October 31, 2026, at the end of Q3, with Barry remaining as a strategic advisor for six months thereafter. The board highlighted Bonfig's role in key growth initiatives like the U.S. online Marketplace and Best Buy Ads, praising Barry's seven-year leadership through challenges. No immediate financial impacts were disclosed, but the transition is positioned as smooth with positive internal endorsement.

• ·Bonfig joined Best Buy in 1999 as an inventory analyst.
• ·Barry is the second-longest tenured CEO in Best Buy's history.
• ·Investor contact: Mollie O'Brien (mollie.obrien@bestbuy.com); Media contact: Carly Charlson (carly.charlson@bestbuy.com)

22-04-2026

On April 18, 2026, the Board of Directors of Jade Biosciences, Inc. (JBIO) appointed Andrew King, BVMS, Ph.D. as President, Research & Development, effective immediately. Dr. King previously served as the Company’s Chief Scientific Officer and Head of Research & Development. No changes were made to Dr. King’s compensation in connection with the appointment.

• ·Filing date: April 22, 2026
• ·Event date: April 18, 2026
• ·Principal executive offices: 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453

22-04-2026

US Nuclear Corp. (UCLE) disclosed that Michael Pope resigned as a member of the Board of Directors effective immediately on April 16, 2026, to pursue other opportunities. The resignation did not result from any disagreement with the company's operations, policies, or practices. The 8-K filing was submitted on April 22, 2026.

22-04-2026

Seaboard Corporation held its annual meeting of stockholders on April 20, 2026, where shareholders voted to elect five directors (Ellen S. Bresky, David A. Adamsen, Douglas W. Baena, Paul M. Squires, and Frances B. Shifman), with votes in favor ranging from 811,128 to 893,965 and withheld votes from 7,097 to 89,934. Shareholders also approved, on an advisory basis, the compensation of Named Executive Officers (832,490 for, 66,062 against, 2,510 abstaining) and ratified KPMG LLP as independent auditors for 2026 (929,204 for, 1,502 against, 526 abstaining), with 30,170 broker non-votes on director election and compensation proposals.

• ·Proxy Statement filed on March 6, 2026.
• ·Annual meeting held in Overland Park, Kansas.
• ·No broker non-votes on auditor ratification.

22-04-2026

Goosehead Insurance reported Q1 2026 total revenues of $93.1 million, up 23% YoY, with core revenues increasing 15% to $79.5 million; net income rose to $8.0 million from $2.6 million, and Adjusted EBITDA surged 57% to $24.4 million. Total written premiums grew 13% to $1.1 billion, policies in force increased 14% to 1,973,000, corporate agent headcount rose 13% to 482, while franchise producers grew modestly 3% to 2,150. The company repurchased $49.8 million of shares and issued FY2026 guidance for 10-19% organic revenue growth and 12-20% total written premium growth.

• ·Client Retention of 85% in Q1 2026
• ·FY2026 guidance: Total revenues organic growth 10-19%, Total written premiums growth 12-20%
• ·Line of credit $75.0M with $26.0M drawn as of March 31, 2026
• ·Remaining share repurchase authorization $148.5M as of March 31, 2026
• ·General and administrative expenses increased to $24.0M from $17.6M YoY

22-04-2026

Amgen announced the retirement of David M. Reese, M.D., Executive Vice President and Chief Technology Officer, effective June 30, 2026, following his contributions to innovative medicines, biosimilars, pipeline advancement, and early adoption of AI in R&D since joining in 2005. Effective June 1, 2026, organizational changes to emphasize convergent innovation include appointing James Bradner, M.D., as EVP Research and Development, Artificial Intelligence and Data; Sean Bruich as SVP Chief Technology Officer; Murdo Gordon as EVP Amgen Global Markets and Policy; with Paul Burton, M.D., Ph.D., continuing as SVP Chief Medical Officer. These adjustments aim to integrate biology, data science, and advanced technologies to accelerate medicine discovery and enhance patient engagement.

• ·David M. Reese joined Amgen in 2005 as clinical development leader in oncology; served as EVP R&D from 2018 to 2023.
• ·Amgen part of Dow Jones Industrial Average and Nasdaq-100 Index.
• ·Contacts: Elissa Snook (media, 609-251-1407); Casey Capparelli (investors, 805-447-1746).

22-04-2026

Medpace Holdings, Inc. reported first quarter 2026 revenue of $706.6 million, up 26.5% YoY from $558.6 million, with net new business awards of $618.4 million, up 23.7% YoY from $500.0 million, and EBITDA of $149.4 million, up 25.9% YoY. However, backlog grew only 2.9% to $2,929.2 million from $2,846.0 million, the net book-to-bill ratio was 0.88x, and net income margin declined to 17.5% from 20.5% YoY. President Jesse Geiger announced his retirement effective May 31, 2026, with CEO August Troendle reassuming the President role.

• ·2026 full-year revenue guidance: $2.755B to $2.855B (8.9% to 12.8% growth over 2025 $2.530B revenue).
• ·2026 full-year GAAP net income guidance: $487.0M to $511.0M.
• ·2026 full-year EBITDA guidance: $605.0M to $635.0M.
• ·Q1 2026 SG&A expenses: $47.9M, down from $57.9M in Q1 2025.

22-04-2026

Procore Technologies, Inc. (NYSE: PCOR) appointed Vishal Misra, RKS Family Professor of Computer Science and Vice Dean of Computing and AI at Columbia University, to its Board of Directors on April 22, 2026. Misra, an accomplished entrepreneur who founded Infinio and AskHereFirst, and co-founded Cricinfo (acquired by ESPN), will bolster Procore's AI expertise amid surging demand for infrastructure. The company has powered over three million projects across 150+ countries with its AI-driven construction management platform.

• ·Misra has served as professor at Columbia University for nearly 25 years.
• ·Misra earned B.Tech. from IIT Bombay, M.S. and Ph.D. from University of Massachusetts Amherst.
• ·Served on Board of Directors of DB Digital and invented live-microblogging at Cricinfo.

22-04-2026

The Beauty Health Company announced a corporate rebrand to SkinHealth Systems Inc., effective immediately, while continuing to trade on the Nasdaq Capital Market under the ticker symbol 'SKIN', with the new name reflected on Nasdaq starting April 23, 2026. This rebrand signifies the company's evolution into a clinically driven, science-backed medical aesthetics platform, anchored by its flagship Hydrafacial product and complemented by SkinStylus and HydraScalp with Keravive. SkinHealth Systems maintains one of the largest installed bases in the aesthetics industry with more than 36,000 devices worldwide.

• ·New website: www.SkinHealthSystems.com
• ·Provider locator: hydrafacial.com/find-a-hydrafacialist
• ·Operates in North America, Europe, and Asia-Pacific

22-04-2026

Kinder Morgan reported Q1 2026 net income attributable to KMI of $976 million, up 36% YoY from $717 million, Adjusted Net Income of $1,063 million (up 39%), Adjusted EBITDA of $2,539 million (up 18%), and Adjusted EPS of $0.48 (up 41%), driven by strong Natural Gas Pipelines performance. However, refined products volumes declined 2% YoY and crude/condensate volumes fell 12% YoY, while 2026 net income outlook remains flat at $3.1 billion despite modest 2-5% growth in adjusted metrics. The company approved a 2% higher dividend of $0.2975 per share, received a Moody's upgrade to Baa1, announced COO retirement and succession, and agreed to acquire Monument Pipeline for $505 million.

• ·Net Debt-to-Adjusted EBITDA ratio ended Q1 2026 at 3.6 times; expected 3.8 times at end-2026.
• ·Project backlog $10.1B, up $145M from Q4 2025; $8.9B (ex-CO2/gathering) with 5.6x first-full-year Project EBITDA multiple.
• ·Annual average utilization of five major natural gas pipeline systems reached 90% in 2025 vs 74% in 2016.
• ·Moody’s upgraded senior unsecured rating to Baa1 (stable outlook) on March 12, 2026.
• ·James Holland retiring as COO effective September 4, 2026; succeeded by Ken Grubb.

22-04-2026

Citizens Financial Services, Inc. held its 2026 annual meeting of shareholders on April 21, 2026, in Wellsboro, Pennsylvania, where five Class 3 directors—Randall E. Black, Joseph B. Bower, Jr., Rinaldo A. DePaola, Janie M. Hilfiger, and Mickey L. Jones—were elected to serve three-year terms until the April 2029 annual meeting. Shareholders ratified the appointment of S.R. Snodgrass, A.C., Certified Public Accountants as independent auditor for the fiscal year ending December 31, 2026, approved the Citizens Financial Services, Inc. 2026 Equity Incentive Plan, and approved the compensation of named executive officers as disclosed in the proxy statement.

• ·Retained directors not standing for election: Robert W. Chappell, Roger C. Graham, Jr., R. Joseph Landy, John P. Painter II, Thomas E. Freeman, Christopher W. Kunes, Terry B. Osborne, and David Z. Richards, Jr.
• ·Meeting location: 11499 Route 6, Wellsboro, Pennsylvania.

22-04-2026

Okta, Inc. announced that Larissa Schwartz intends to leave her role as Chief Legal Officer and Corporate Secretary effective July 31, 2026, transitioning to a senior advisor role through January 31, 2027. During the transition, she will continue receiving her current base salary until July 31, 2026, followed by a monthly base salary of $21,483, with continued benefits and equity vesting eligibility. She is also eligible for a lump-sum severance payment equal to nine months of her current base salary upon execution of a release of claims.

• ·Transition and separation agreement dated April 21, 2026, to be filed as exhibit to Form 10-Q for quarter ending April 30, 2026.
• ·Event reported as of April 21, 2026; filing dated April 22, 2026.

22-04-2026

NB Bancorp reported Q1 2026 net income of $15.0 million ($0.36 per diluted share), up from $7.7 million ($0.19) in the prior quarter, driven by net interest income growth of 10.4% to $64.9 million and net interest margin expansion to 3.94% (up 2 bps QoQ). Loans grew 3.7% to $6.21 billion and total deposits increased 4.2% to $6.10 billion. However, operating net income declined to $15.8 million ($0.38/share) from $21.2 million ($0.51), provision for credit losses swung to an expense of $6.3 million from a $1.1 million release, and salaries/employee benefits rose 20.5% due to headcount growth post-acquisition.

• ·Quarterly cash dividend of $0.07 per share declared, payable May 20, 2026 to shareholders of record May 6, 2026.
• ·Allowance for credit losses $80.2 million (1.29% of total loans) at Q1 end, down from $87.4 million (1.46%).
• ·Commercial and industrial loans up 13.4% QoQ; multi-family residential loans up 4.0% QoQ.
• ·Noninterest expense down 13.4% overall to $42.7 million, driven by 96.6% drop in merger expenses.

22-04-2026

Barinthus Biotherapeutics plc appointed Douglas Swirsky as Chief Financial Officer and principal accounting officer, effective May 1, 2026. Mr. Swirsky brings over 25 years of experience, including prior CFO roles at MaxCyte, Inc. and AavantiBio, Inc., and will provide services via a master services agreement with Grand Strand BioAdvisors LLC for a monthly fee of $20,000. No family relationships or undisclosed arrangements exist with directors or officers.

• ·Douglas Swirsky, age 56, is a certified public accountant in Maryland and CFA charterholder; holds B.S. from Boston University and M.B.A. from Northwestern University Kellogg School.
• ·Currently serves as chairman of Cellectar Biosciences, Inc. board and Senior Advisor to MaxCyte’s CEO.
• ·MSA includes D&O liability insurance and indemnification for Mr. Swirsky on terms no less favorable than other officers.

22-04-2026

On April 22, 2026, Quince Therapeutics, Inc. increased its Board of Directors from three to four members and appointed June Bray as a Class I director, effective immediately, until the 2026 Annual Meeting of Stockholders. The Board determined Ms. Bray to be independent under Nasdaq standards and appointed her to the Nominating & Governance Committee, Audit Committee, and Compensation Committee. Ms. Bray will receive standard non-employee director compensation, including a $38,000 annual Board retainer plus $7,500, $5,500, and $4,000 for her committee services, but no initial option grant.

• ·Board size increased to four directors.
• ·Ms. Bray has no family relationships with directors or officers and no material interests under Item 404(a) of Regulation S-K.
• ·Compensation per Outside Director Compensation Policy (Exhibit 10.14 to 10-K filed April 10, 2026).
• ·Standard indemnification agreement (Exhibit 10.4 to 10-K filed April 10, 2026).

22-04-2026

MasterBrand, Inc. (MBC) filed an 8-K on April 22, 2026, reporting under Items 5.02 (Director/Officer Departure/Election) and 8.01 (Entry into a Material Definitive Agreement), with an event date of April 17, 2026. The filing cross-references risk factors from its own 10-Q for the quarterly period ended October 31, 2025, and American Woodmark’s 10-Q for the period ended January 31, 2026, along with standard forward-looking statements and no-offer disclaimers. It was signed by R. David Banyard, Jr., President & Chief Executive Officer.

22-04-2026

GigaCloud Technology Inc (Nasdaq: GCT) announced the planned retirement of Marshall Bernes, Head of Brand Center, from his executive officer position within the next six months, while he will continue serving on the Board of Directors. The company has initiated a transition and succession planning process to appoint seasoned professionals, ensuring operational continuity for the Brand Center, which oversees product design and branding. Mr. Bernes, founder of Noble House, contributed to its integration, Brand Center development, and brand relationships over the past three years.

• ·Marketplace first launched in January 2019
• ·Filing date: April 22, 2026

22-04-2026

Prairie Operating Co. (Nasdaq: PROP) announced the resignation of Gizman I. Abbas from its Board of Directors, effective May 15, 2026, which was not due to any disagreement with the company on operations, policies, or practices. During his tenure, Mr. Abbas served on the Compensation, Audit, and chaired the Nominating and Governance Committees. The Chairman, Interim CEO, and Mr. Abbas himself expressed mutual appreciation for his contributions and confidence in the company's ongoing strategy.

• ·Announcement issued from Houston, Texas, on April 22, 2026.
• ·Company focused on development and acquisition in the oil and liquids-rich regions of the DJ Basin.

22-04-2026

PubMatic reported preliminary Q1 2026 revenue of $62.4 million and adjusted EBITDA of $2.5 million, exceeding prior guidance of $58.0-60.0 million in revenue and $(0.5)-$1.0 million in adjusted EBITDA. However, Chief Growth Officer Paulina Klimenko and Chief Revenue Officer for the Americas Kyle Dozeman are departing for personal reasons, leading to a search for a global Chief Revenue Officer via Heidrick & Struggles. The company emphasized strong momentum in agentic AI solutions amid these leadership transitions.

• ·Q1 2026 ended March 31, 2026; full audited results and earnings webcast scheduled for May 7, 2026 at 1:30pm PT.
• ·Paulina Klimenko to remain in role through July 2026 for transition.
• ·Kyle Dozeman to remain through end of May 2026 and continue in advisory capacity thereafter.

22-04-2026

Effective April 16, 2026, Tao Tu resigned as a director of Inno Holdings Inc., also stepping down from the Audit and Compensation Committees, with no disagreements with the Company on operations, policies, or practices. On April 20, 2026, the Board appointed Shenghui Zhu, age 39 with over a decade of experience in the electronic products industry from roles at P&T Electronic Technology Co., Ltd. and Gecko Electronics Limited, as a replacement director and independent member of the Audit and Compensation Committees. The Company entered into an indemnification agreement with Mr. Zhu, with no family relationships, arrangements, or related party transactions disclosed.

• ·Mr. Zhu received a Bachelor of Engineering in Electronic Information Engineering from Jiangxi University of Science and Technology in September 2010.
• ·No arrangements or understandings pursuant to which Mr. Zhu was elected to the Board.
• ·Exhibit 10.1: Form of Indemnification Agreement (incorporated by reference from Form S-1 filed October 20, 2023).

22-04-2026

OSR Holdings, Inc. appointed Yeiseok Kim, age 36, as Chief Operating Officer effective April 16, 2026, following Board approval on March 26, 2026. Mr. Kim, with prior experience as Senior Analyst at subsidiary OSR Holdings Co., Ltd. supporting cross-border healthcare investments and pharmaceutical licensing, brings medical expertise from his Korean medical license (2019), MS in Medicine (2019), and BA (2013). His amended employment agreement provides a base salary of KRW 240,000,000 per year, discretionary equity-based compensation, and customary benefits, with no related arrangements, family relationships, or material interests disclosed.

• ·Mr. Kim's prior roles: Senior Analyst at OSR Holdings Co., Ltd. (2020-2025); Korean medical license (2019).
• ·Education: BA in Environmental Science from Seoul National University (2013); MS in Medicine from Jeonbuk National University (2019).

22-04-2026

Spectral AI, Inc. issued an employment offer to Vincent S. Capone as Chief Executive Officer of Spectral MD, Inc. and its parent Spectral AI, Inc., effective February 9, 2026, with an annual base salary of $500,000 and eligibility for a discretionary annual bonus up to 100% of salary (minimum $250,000). The offer includes a grant of 200,000 RSUs vesting 50% on April 1, 2026, and 50% on April 1, 2027, subject to board approval, along with standard benefits like 401(k) matching up to 6% and PTO accrual of 10 hours per month. Potential board nomination is targeted no later than the 2027 annual shareholders' meeting.

• ·Severance upon termination without Cause or for Good Reason: 12 months of continued salary and benefits, full vesting of equity, and extended option exercise period, conditioned on release of claims.
• ·At-will employment with detailed definitions of Cause and Disability.
• ·Confidentiality: Offer terms confidential for employee except to family/advisors; company may disclose freely.
• ·Governed by Texas law; disputes in Dallas courts.

22-04-2026

Tenax Therapeutics, Inc. (Nasdaq: TENX) appointed Thomas R. Staab, II as Chief Financial Officer effective May 11, 2026, replacing interim CFO Thomas McGauley who modernized the finance organization. Mr. Staab brings over 25 years of financial leadership experience, including roles at LENSAR, BioCryst Pharmaceuticals, Inspire Pharmaceuticals (acquired by Merck for $430M), and Triangle Pharmaceuticals (acquired by Gilead for $464M). In connection with his appointment, the company issued inducement equity awards of 10,000 restricted stock units and options to purchase 450,000 shares of common stock, approved under Nasdaq Listing Rule 5635(c)(4).

• ·One quarter of RSUs vest 10 days after start date, remainder in three equal installments on four-, eight-, and twelve-month anniversaries.
• ·One quarter of options vest on first anniversary, remainder in 36 monthly installments.
• ·Mr. Staab holds BS in Business Administration and Master of Accounting from University of North Carolina at Chapel Hill; Certified Public Accountant.
• ·Equity awards subject to continued employment through vesting dates; option exercise price is closing stock price on grant date.

22-04-2026

On April 17, 2026, Greenland Mines Ltd. (formerly Klotho Neurosciences, Inc., ticker GRML) appointed Jason D. Sawyer, age 54, as a new member of its Board of Directors to fill a vacancy, effective immediately, until the next annual stockholder meeting. Mr. Sawyer, General Manager of Access Alternative Group S.A., has 33 years in alternative investments, with firms he was principal in raising more than $5 billion in assets and deploying over US$300 million in early/growth-stage investments across multiple sectors. He currently serves on boards of GridAI Technologies Corp. (GRDX), Quantum BioPharma (QNTM), The FUTR Corp. (FTRC), Lixte Biotechnology Holdings, Inc. (LIXT), and Perpetuals.com (PDC), with no family ties, related transactions, or committee assignments at Greenland Mines Ltd.

• ·Mr. Sawyer has not entered into any agreement with the Company in connection with his appointment.
• ·Mr. Sawyer is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
• ·No committees assigned to Mr. Sawyer at this time.
• ·Filing signed by Joseph Sinkule on April 22, 2026.

22-04-2026

Regal Rexnord Corporation (NYSE: RRX) announced the appointment of Aamir Paul as its next Chief Executive Officer, effective no later than July 1, 2026, succeeding current CEO Louis Pinkham, who will ensure a smooth transition and resign from the Board upon departure. Paul, aged 48 and currently President of North America at Schneider Electric SE, grew that business at double-digit rates through 2025, generating over $17 billion in revenue, employing over 43,000 people, and operating over 35 manufacturing facilities. The Board praised Paul's track record in sales, strategy, operations, and key growth markets like data centers and discrete automation, with no reported concerns on the transition.

• ·CEO search initiated on October 29, 2025.
• ·First quarter earnings conference call scheduled for May 7, 2026.
• ·Regal Rexnord operates in three segments: Automation & Motion Control, Industrial Powertrain Solutions, and Power Efficiency Solutions.
• ·Aamir Paul previously spent over 13 years at Dell Technologies, culminating as SVP, Global Server Solutions Sales.

22-04-2026

T. Rowe Price Group, Inc. amended and restated the employment agreement with Glenn R. August, continuing his role as Chief Executive Officer of subsidiary Oak Hill Advisors, L.P., effective April 21, 2026. The agreement provides for an annual base salary of $350,000, eligibility for annual bonuses and equity awards at board discretion, 30 days of paid time off, and standard employee benefits. It details termination provisions including notice periods, cause definitions, and severance-like benefits upon death or disability.

• ·Executive reports directly to the CEO of T. Rowe Price Group, Inc.; principal place of employment is New York, NY, with remote work permitted.
• ·Termination for Cause requires written notice, 30-day cure period (if curable), and Board approval; without Cause requires 60 days' notice.
• ·Good Reason termination defined as material diminution in salary/duties or Company breach, with 30-day cure period for Company.
• ·Upon death or disability: Accrued Benefits plus 6 months of monthly base salary continuation and COBRA subsidy.

22-04-2026

Shmuel S.Z. Lieberman resigned as an independent director of Sonida Senior Living, Inc. effective April 27, 2026, with no disagreements on operations, policies, or practices. The Board appointed Sam Levinson, a designee of stockholder Silk Partners LP pursuant to the March 10, 2026 Investor Rights Agreement, as a Class II director and to the Compensation Committee effective the same date; his term expires at the 2026 annual stockholders' meeting. The Board determined Mr. Levinson qualifies as independent under NYSE listing standards.

• ·Resignation notice and appointment both occurred on April 16, 2026.
• ·No transactions involving Mr. Levinson, Silk, or affiliates required disclosure under Item 404(a) of Regulation S-K.
• ·References prior 8-K filings: November 5, 2025 (Investor Rights Agreement); February 6, 2024 (Securities Purchase Agreement).

22-04-2026

Delek US Holdings, Inc. held its 2026 Annual Meeting on April 20, 2026, where stockholders elected all ten director nominees, including Ezra Uzi Yemin and Vasiliki (Vicky) Sutil who faced relatively higher opposition votes of 3,042,165. Stockholders also approved the 2026 Long-Term Incentive Plan (41,468,551 for vs. 5,175,365 against, replacing the 2016 plan), an advisory vote on executive compensation (46,352,822 for), and ratification of Ernst & Young LLP as auditors (50,568,148 for). All proposals passed with majority support despite some notable opposition on director elections and the incentive plan.

• ·No further awards will be made under the 2016 Long-Term Incentive Plan
• ·Quorum present at the Annual Meeting
• ·Exhibits include 2026 Plan document and forms of RSU, PRSU, and Stock Appreciation Right award agreements

22-04-2026

First Guaranty Bancshares, Inc. elected Ms. Betsy K. Hood to its Board of Directors on April 16, 2026. Ms. Hood, a graduate of Southeastern Louisiana University with over 25 years of experience in the retail automotive industry, serves as Dealer Principal of Hood Automotive Group and President of Southern Dealers Mechanical Breakdown Insurance. She has not been appointed to any board committees and is not a party to any disclosable transactions with the company under Item 404(a) of Regulation S-K.

• ·Ms. Hood currently serves on the Board of Directors of the Southeastern Lion Athletic Association and the Louisiana Children's Discovery Center.